Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer

World Journal of Gastroenterology

Volumn 20, Issue 31, 2014, Pages 10758-10768

  Bournet, Barbara ^a   Gayral, Marion ^a   Torrisani, Jérôme ^a   Selves, Janick ^a,b   Cordelier, Pierre ^a   Buscail, Louis ^a  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

Author keywords

Chronic pancreatitis; Endoscopic ultrasound guided fine needle aspiration; KRAS mutation assay; Micro RNA; Pancreatic ductal adenocarcinoma; qPCR analysis; Solid pancreatic mass

Indexed keywords

CALCYCLIN; GEMCITABINE; K RAS PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 10B; MUCIN; MUCIN 1; MUCIN 2; MUCIN 5AC; PROTEIN P53; SMALL UNTRANSLATED RNA; UROKINASE RECEPTOR; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHRONIC PANCREATITIS; CYTOPATHOLOGY; DIFFERENTIAL DIAGNOSIS; DNA EXTRACTION; DNA METHYLATION; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; FALSE NEGATIVE RESULT; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR DIAGNOSIS; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS JUICE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA EXTRACTION; TREATMENT RESPONSE; TUMOR INVASION; CARCINOMA, PANCREATIC DUCTAL; CHEMISTRY; GENETICS; PANCREATIC NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; TREATMENT OUTCOME;

CARCINOMA, PANCREATIC DUCTAL; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; HUMANS; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUCINS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84909605984     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i31.10758     Document Type: Review

References (87)

1. Hidalgo M, Maitra A. The hedgehog pathway and pancreatic cancer. N Engl J Med 2009; 361: 2094-2096 [PMID: 19923581 DOI: 10.1056/NEJMra0901557]
2. Buscail L, Faure P, Bournet B, Selves J, Escourrou J. Interventional endoscopic ultrasound in pancreatic diseases. Pancreatology 2006; 6: 7-16 [PMID: 16327280]
3. Savides TJ, Donohue M, Hunt G, Al-Haddad M, Aslanian H, Ben-Menachem T, Chen VK, Coyle W, Deutsch J, DeWitt J, Dhawan M, Eckardt A, Eloubeidi M, Esker A, Gordon SR, Gress F, Ikenberry S, Joyce AM, Klapman J, Lo S, Maluf-Filho F, Nickl N, Singh V, Wills J, Behling C. EUS-guided FNA diagnostic yield of malignancy in solid pancreatic masses: a benchmark for quality performance measurement. Gastrointest Endosc 2007; 66: 277-282 [PMID: 17643700]
4. Al-Haddad M, Eloubeidi MA. Interventional EUS for the diagnosis and treatment of locally advanced pancreatic cancer. JOP 2010; 11: 1-7 [PMID: 20065544]
5. Yoshinaga S, Suzuki H, Oda I, Saito Y. Role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for diagnosis of solid pancreatic masses. Dig Endosc 2011; 23 Suppl 1: 29-33 [PMID: 21535197 DOI: 10.1111/j.1443-1661.2011.01112.x]
6. Kato K, Kamada H, Fujimori T, Aritomo Y, Ono M, Masaki T. Molecular Biologic Approach to the Diagnosis of Pancreatic Carcinoma Using Specimens Obtained by EUS-Guided Fine Needle Aspiration. Gastroenterol Res Pract 2012; 2012: 243524 [PMID: 23197977 DOI: 10.1155/2012/243524]
7. Siddiqui AA, Brown LJ, Hong SK, Draganova-Tacheva RA, Korenblit J, Loren DE, Kowalski TE, Solomides C. Relationship of pancreatic mass size and diagnostic yield of endoscopic ultrasound-guided fine needle aspiration. Dig Dis Sci 2011; 56: 3370-3375 [PMID: 21688127 DOI: 10.1007/s10620-011-1782-z]
8. Bang JY, Hebert-Magee S, Trevino J, Ramesh J, Varadarajulu S. Randomized trial comparing the 22-gauge aspiration and 22-gauge biopsy needles for EUS-guided sampling of solid pancreatic mass lesions. Gastrointest Endosc 2012; 76: 321-327 [PMID: 22658389 DOI: 10.1016/j.gie.2012.03.1392]
9. Janssen J, Schlörer E, Greiner L. EUS elastography of the pancreas: feasibility and pattern description of the normal pancreas, chronic pancreatitis, and focal pancreatic lesions. Gastrointest Endosc 2007; 65: 971-978 [PMID: 17531630]
10. Kitano M, Sakamoto H, Matsui U, Ito Y, Maekawa K, von Schrenck T, Kudo M. A novel perfusion imaging technique of the pancreas: contrast-enhanced harmonic EUS (with video). Gastrointest Endosc 2008; 67: 141-150 [PMID: 18155437]
11. Hirche TO, Ignee A, Barreiros AP, Schreiber-Dietrich D, Jungblut S, Ott M, Hirche H, Dietrich CF. Indications and limitations of endoscopic ultrasound elastography for evaluation of focal pancreatic lesions. Endoscopy 2008; 40: 910-917 [PMID: 19009483 DOI: 10.1055/s-2008-1077726]
12. Ryozawa S, Iwano H, Taba K, Sen-yo M, Uekitani T. Genetic diagnosis of pancreatic cancer using specimens obtained by EUS-FNA. Dig Endosc 2011; 23 Suppl 1: 43-45 [PMID: 21535200 DOI: 10.1111/j.1443-1661.2011.01117.x]
13. Khalid A, Nodit L, Zahid M, Bauer K, Brody D, Finkelstein SD, McGrath KM. Endoscopic ultrasound fine needle aspirate DNA analysis to differentiate malignant and benign pancreatic masses. Am J Gastroenterol 2006; 101: 2493-2500 [PMID: 17029619]
14. Brais RJ, Davies SE, O'Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP, Neesse A, Lockley M, Corrie PG, Jodrell DI, Praseedom RK, Huguet EL, Jah A, Jamieson NV, de Sauvage FJ, Tuveson DA, Carroll NR. Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. Pancreatology 2012; 12 : 8-15 [PMID: 22487467 DOI: 10.1016/j.pan.2011.12.009]
15. Varadarajulu S, Hasan MK, Bang JY, Hebert-Magee S, Hawes RH. Endoscopic ultrasound-guided tissue acquisition. Dig Endosc 2014; 26 Suppl 1: 62-69 [PMID: 24033879 DOI: 10.1111/den.12146]
16. Hamada S, Shimosegawa T. Biomarkers of pancreatic cancer. Pancreatology 2011; 11 Suppl 2: 14-19 [PMID: 21464582 DOI: 10.1159/000323479]
17. Mishra G. DNA analysis of cells obtained from endoscopic ultrasound-fine needle aspiration in pancreatic adenocarcinoma: Fool's Gold, Pandora's Box, or Holy Grail? Am J Gastroenterol 2006; 101: 2501-2503 [PMID: 17090279]
18. Bournet B, Pointreau A, Delpu Y, Selves J, Torrisani J, Buscail L, Cordelier P. Molecular endoscopic ultrasound for diagnosis of pancreatic cancer. Cancers (Basel) 2011; 3: 872-882 [PMID: 24212643 DOI: 10.3390/cancers3010872]
19. Van Laethem JL, Vertongen P, Deviere J, Van Rampelbergh J, Rickaert F, Cremer M, Robberecht P. Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours. Gut 1995; 36: 781-787 [PMID: 7797131]
20. Berthélemy P, Bouisson M, Escourrou J, Vaysse N, Rumeau JL, Pradayrol L. Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 1995; 123: 188-191 [PMID: 598300]
21. Costentin L, Pagès P, Bouisson M, Berthelémy P, Buscail L, Escourrou J, Pradayrol L, Vaysse N. Frequent deletions of tumor suppressor genes in pure pancreatic juice from patients with tumoral or nontumoral pancreatic diseases. Pancreatology 2002; 2: 17-25 [PMID: 12120000]
22. Hanoun N, Delpu Y, Suriawinata AA, Bournet B, Bureau C, Selves J, Tsongalis GJ, Dufresne M, Buscail L, Cordelier P, Torrisani J. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin Chem 2010; 56: 1107-1118 [PMID: 20431052 DOI: 10.1373/clinchem.2010.144709]
23. Bournet B, Pointreau A, Souque A, Oumouhou N, Muscari F, Lepage B, Senesse P, Barthet M, Lesavre N, Hammel P, Levy P, Ruszniewski P, Cordelier P, Buscail L. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. Pancreatology 2012; 12: 27-34 [PMID: 22487470 DOI: 10.1016/j.pan.2011.12.003]
24. Szafranska AE, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, Barth RJ, Gutmann EJ, Suriawinata AA, Marc Pipas J, Tannapfel A, Korc M, Hahn SA, Labourier E, Tsongalis GJ. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 2008; 54 : 1716-1724 [PMID: 18719196 DOI: 10.1373/clinchem.2008.109603]
25. Hahn SA, Schmiegel WH. Recent discoveries in cancer genetics of exocrine pancreatic neoplasia. Digestion 1998; 59: 493-501 [PMID: 9705534]
26. Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A. Pancreatic carcinogenesis. Pancreatology 2008; 8 : 110-125 [PMID: 18382097 DOI: 10.1159/000123838]
27. Wang X, Gao J, Ren Y, Gu J, Du Y, Chen J, Jin Z, Zhan X, Li Z, Huang H, Lv S, Gong Y. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis. Am J Gastroenterol 2011; 106: 2104-2111 [PMID: 21876563 DOI: 10.1038/ajg.2011.281]
28. Bournet B, Souque A, Senesse P, Assenat E, Barthet M, Lesavre N, Aubert A, O'Toole D, Hammel P, Levy P, Ruszniewski P, Bouisson M, Escourrou J, Cordelier P, Buscail L. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis. Endoscopy 2009; 41: 552-557 [PMID: 19533561 DOI: 10.1055/s-0029-1214717]
29. Ogura T, Yamao K, Sawaki A, Mizuno N, Hara K, Hijioka S, Niwa Y, Tajika M, Kondo S, Shimizu Y, Bhatia V, Higuchi K, Hosoda W, Yatabe Y. Clinical impact of K-ras mutation analysis in EUS-guided FNA specimens from pancreatic masses. Gastrointest Endosc 2012; 75: 769-774 [PMID: 22284089 DOI: 10.1016/j.gie.2011.11.012]
30. Reicher S, Boyar FZ, Albitar M, Sulcova V, Agersborg S, Nga V, Zhou Y, Li G, Venegas R, French SW, Chung DS, Stabile BE, Eysselein VE, Anguiano A. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses. Pancreas 2011; 40: 1057-1062 [PMID: 21705950 DOI: 10.1097/MPA.0b013e3182200201]
31. Tada M, Komatsu Y, Kawabe T, Sasahira N, Isayama H, Toda N, Shiratori Y, Omata M. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol 2002; 97: 2263-2270 [PMID: 12358243]
32. Ginestà MM, Mora J, Mayor R, Farré A, Peinado MA, Busquets J, Serrano T, Capellá G, Fabregat J. Genetic and epigenetic markers in the evaluation of pancreatic masses. J Clin Pathol 2013; 66: 192-197 [PMID: 23135349 DOI: 10.1136/jclin-path-2012-201123]
33. Maluf-Filho F, Kumar A, Gerhardt R, Kubrusly M, Sakai P, Hondo F, Matuguma SE, Artifon E, Monteiro da Cunha JE, César Machado MC, Ishioka S, Forero E. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass. J Clin Gastroenterol 2007; 41: 906-910 [PMID: 18090159]
34. Takahashi K, Yamao K, Okubo K, Sawaki A, Mizuno N, Ashida R, Koshikawa T, Ueyama Y, Kasugai K, Hase S, Kakumu S. Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA. Gastrointest Endosc 2005; 61: 76-79 [PMID: 15672060]
35. Pellisé M, Castells A, Ginès A, Solé M, Mora J, Castellví-Bel S, Rodríguez-Moranta F, Fernàndez-Esparrach G, Llach J, Bordas JM, Navarro S, Piqué JM. Clinical usefulness of KRAS mutational analysis in the diagnosis of pancreatic adenocarcinoma by means of endosonography-guided fineneedle aspiration biopsy. Aliment Pharmacol Ther 2003; 17: 1299-1307 [PMID: 12755843]
36. Khalid A, Dewitt J, Ohori NP, Chen JH, Fasanella KE, Sanders M, McGrath KM, Nikiforova M. EUS-FNA mutational analysis in differentiating autoimmune pancreatitis and pancreatic cancer. Pancreatology 2011; 11 : 482-486 [PMID: 21997479 DOI: 10.1159/000331505]
37. Ogura T, Yamao K, Hara K, Mizuno N, Hijioka S, Imaoka H, Sawaki A, Niwa Y, Tajika M, Kondo S, Tanaka T, Shimizu Y, Bhatia V, Higuchi K, Hosoda W, Yatabe Y. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol 2013; 48: 640-646 [PMID: 22983505 DOI: 10.1007/s00535-012-0664-2]
38. Didelot A, Le Corre D, Luscan A, Cazes A, Pallier K, Emile JF, Laurent-Puig P, Blons H. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol 2012; 92: 275-280 [PMID: 22426079 DOI: 10.1016/j.yexmp.2012.03.001]
39. Bournet B, Selves J, Grand D, Danjoux M, Hanoun N, Cordelier P, Buscail L. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer. J Clin Gastroenterol 2014; In press
40. Oliveira-Cunha M, Hadfield KD, Siriwardena AK, Newman W. EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer. Pancreas 2012; 41: 428-434 [PMID: 22422135 DOI: 10.1097/MPA.0b013e3182327a03]
41. da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 2010; 116: 5599-5607 [PMID: 20824720 DOI: 10.1002/cncr.25393]
42. Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger MM, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A, Endlicher E. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. Oncology 2011; 81: 3-8 [PMID: 21894049 DOI: 10.1159/000330194]
43. Bournet B, Muscari F, Guimbaud R, Cordelier P, Buscail L. KRAS mutations and their correlation with survival of patients with advanced pancreatic cancer. Pancreas 2013; 42: 543-544 [PMID: 23486365 DOI: 10.1097/MPA.0b013e31826b388b]
44. Kim ST, Lim do H, Jang KT, Lim T, Lee J, Choi YL, Jang HL, Yi JH, Baek KK, Park SH, Park YS, Lim HY, Kang WK, Park JO. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther 2011; 10: 1993-1999 [PMID: 21862683 DOI: 10.1158/1535-7163.MCT-11-0269]
45. Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, Hughes SJ, Bartlett DL, Zeh HJ, Moser AJ. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J Gastrointest Surg 2008; 12: 1664-1672; discussion 1672-1673 [PMID: 18677542 DOI: 10.1007/s11605-008-0577-9]
46. Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K, Park JO. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007; 109: 1561-1569 [PMID: 17354229]
47. Itoi T, Takei K, Sofuni A, Itokawa F, Tsuchiya T, Kurihara T, Nakamura K, Moriyasu F, Tsuchida A, Kasuya K. Immuno-histochemical analysis of p53 and MIB-1 in tissue specimens obtained from endoscopic ultrasonography-guided fine needle aspiration biopsy for the diagnosis of solid pancreatic masses. Oncol Rep 2005; 13: 229-234 [PMID: 15643503]
48. Jahng AW, Reicher S, Chung D, Varela D, Chhablani R, Dev A, Pham B, Nieto J, Venegas RJ, French SW, Stabile BE, Eysselein VE. Staining for p53 and Ki-67 increases the sensitivity of EUS-FNA to detect pancreatic malignancy. World J Gastrointest Endosc 2010; 2: 362-368 [PMID: 21173913 DOI: 10.4253/wjge.v2.i11.362]
49. Salek C, Benesova L, Zavoral M, Nosek V, Kasperova L, Ryska M, Strnad R, Traboulsi E, Minarik M. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J Gastroenterol 2007; 13: 3714-3720 [PMID: 17659731]
50. Gheonea DI, Ciurea ME, Sãftoiu A, Ioana M. Quantitative RT-PCR analysis of MMR genes on EUS-guided FNA samples from focal pancreatic lesions. Hepatogastroenterology 2012; 59: 916-920 [PMID: 22020914 DOI: 10.5754/hge11463]
51. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297 [PMID: 14744438]
52. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009; 10 : 126-139 [PMID: 19165215 DOI: 10.1038/nrm2632]
53. Redis RS, Berindan-Neagoe I, Pop VI, Calin GA. Noncoding RNAs as theranostics in human cancers. J Cell Biochem 2012; 113: 1451-1459 [PMID: 22213511 DOI: 10.1002/jcb.24038]
54. Li M, Marin-Muller C, Bharadwaj U, Chow KH, Yao Q, Chen C. MicroRNAs: control and loss of control in human physiology and disease. World J Surg 2009; 33: 667-684 [PMID: 19030926 DOI: 10.1007/s00268-008-9836-x]
55. du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, Tsongalis GJ, Suriawinata AA, Carrère N, Buscail L, Cordelier P. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010; 56: 603-612 [PMID: 20093556 DOI: 10.1373/clinchem.2009.137364]
56. Choi MR, In YH, Park J, Park T, Jung KH, Chai JC, Chung MK, Lee YS, Chai YG. Genome-scale DNA methylation pattern profiling of human bone marrow mesenchymal stem cells in long-term culture. Exp Mol Med 2012; 44: 503-512 [PMID: 22684242 DOI: 10.3858/emm.2012.44.8.057]
57. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009; 27: 5848-5856 [PMID: 19884536 DOI: 10.1200/JCO.2009.24.0317]
58. Torrisani J, Bournet B, du Rieu MC, Bouisson M, Souque A, Escourrou J, Buscail L, Cordelier P. let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther 2009; 20: 831-844 [PMID: 19323605 DOI: 10.1089/hum.2008.134]
59. Delpu Y, Lulka H, Sicard F, Saint-Laurent N, Lopez F, Hanoun N, Buscail L, Cordelier P, Torrisani J. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool. PLoS One 2013; 8: e55513 [PMID: 23383211 DOI: 10.1371/journal.pone.0055513]
60. 60 Habbe N, Koorstra JB, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, Mullendore ME, Goggins MG, Hong SM, Maitra A. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 2009; 8: 340-346 [PMID: 19106647 DOI: 10.4161/cbt.8.4.7338]
61. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009; 2: 807-813 [PMID: 19723895 DOI: 10.1158/1940-6207. CAPR-09-0094]
62. Cui SY, Wang R, Chen LB. MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers. J Cell Mol Med 2013; 17: 1207-1217 [PMID: 24106980 DOI: 10.1111/jcmm.12131]
63. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297: 1901-1908 [PMID: 17473300 DOI: 10.1001/jama.297.17.1901]
64. Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H, Nakata K, Tanaka M. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer 2010; 9: 169 [PMID: 20579395 DOI: 10.1186/1476-4598-9-169]
65. Steele CW, Oien KA, McKay CJ, Jamieson NB. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Pancreas 2011; 40: 1165-1171 [PMID: 22001830 DOI: 10.1097/MPA.0b013e3182218ffb]
66. Szafranska-Schwarzbach AE, Adai AT, Lee LS, Conwell DL, Andruss BF. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma. Expert Rev Mol Diagn 2011; 11: 249-257 [PMID: 21463235 DOI: 10.1586/erm.11.10]
67. Preis M, Gardner TB, Gordon SR, Pipas JM, Mackenzie TA, Klein EE, Longnecker DS, Gutmann EJ, Sempere LF, Korc M. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res 2011; 17: 5812-5821 [PMID: 21652542 DOI: 10.1158/1078-0432.CCR-11-0695]
68. Nagata K, Horinouchi M, Saitou M, Higashi M, Nomoto M, Goto M, Yonezawa S. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg 2007; 14: 243-254 [PMID: 17520199]
69. Carrara S, Cangi MG, Arcidiacono PG, Perri F, Petrone MC, Mezzi G, Boemo C, Talarico A, Cin ED, Grassini G, Doglioni C, Testoni PA. Mucin expression pattern in pancreatic diseases: findings from EUS-guided fine-needle aspiration biopsies. Am J Gastroenterol 2011; 106: 1359-1363 [PMID: 21647207 DOI: 10.1038/ajg.2011.22]
70. Giorgadze TA, Peterman H, Baloch ZW, Furth EE, Pasha T, Shiina N, Zhang PJ, Gupta PK. Diagnostic utility of mucin profile in fine-needle aspiration specimens of the pancreas: an immunohistochemical study with surgical pathology correlation. Cancer 2006; 108: 186-197 [PMID: 16628655]
71. Wang Y, Gao J, Li Z, Jin Z, Gong Y, Man X. Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas. Int J Cancer 2007; 121: 2716-2722 [PMID: 17708554]
72. Laurell H, Bouisson M, Berthelemy P, Rochaix P, Dejean S, Besse P, Susini C, Pradayrol L, Vaysse N, Buscail L. Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. World J Gastroenterol 2006; 12: 3344-3351 [PMID: 16733850]
73. Zihao G, Jie Z, Yan L, Jing Z, Jing C, Xue L, Jing Z, Heng LW, Ru G, Jianyu H. Analyzing S100A6 expression in endoscopic ultrasonography-guided fine-needle aspiration specimens: a promising diagnostic method of pancreatic cancer. J Clin Gastroenterol 2013; 47: 69-75 [PMID: 22914344 DOI: 10.1097/MCG.0b013e3182601752]
74. Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F. Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol 2008; 129: 81-88 [PMID: 18089492]
75. Kosarac O, Takei H, Zhai QJ, Schwartz MR, Mody DR. S100P and XIAP expression in pancreatic ductal adenocarcinoma: potential novel biomarkers as a diagnostic adjunct to fine needle aspiration cytology. Acta Cytol 2011; 55 : 142-148 [PMID: 21325798 DOI: 10.1159/000320913]
76. Ohuchida K, Mizumoto K, Ishikawa N, Fujii K, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res 2005; 11: 7785-7793 [PMID: 16278400]
77. Chen Y, Zheng B, Robbins DH, Lewin DN, Mikhitarian K, Graham A, Rumpp L, Glenn T, Gillanders WE, Cole DJ, Lu X, Hoffman BJ, Mitas M. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. Int J Cancer 2007; 120: 1511-1517 [PMID: 17192896]
78. Dim DC, Jiang F, Qiu Q, Li T, Darwin P, Rodgers WH, Peng HQ. The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and 14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration. Diagn Cytopathol 2014; 42: 193-199 [PMID: 21538952 DOI: 10.1002/dc.21684]
79. Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 2000; 60: 6075-6079 [PMID: 11085530]
80. Hapke DM, Stegmann AP, Mitchell BS. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 1996; 56: 2343-2347 [PMID: 8625309]
81. Vernejoul F, Ghénassia L, Souque A, Lulka H, Drocourt D, Cordelier P, Pradayrol L, Pyronnet S, Buscail L, Tiraby G. Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. Mol Ther 2006; 14: 758-767 [PMID: 17000136]
82. Mareacute;chal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, Andreacute; T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012; 143: 664-674. e1-6 [PMID: 22705007 DOI: 10.1053/j.gastro.2012.06.006]
83. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66 : 3928-3935 [PMID: 16585222]
84. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 2010; 12: 807-817 [PMID: 20927319]
85. Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 2010; 116: 5325-5335 [PMID: 20665488 DOI: 10.1002/cncr.25282]
86. Itoi T, Sofuni A, Fukushima N, Itokawa F, Tsuchiya T, Kurihara T, Moriyasu F, Tsuchida A, Kasuya K. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J Gastroenterol 2007; 42: 389-394 [PMID: 17530364]
87. Ashida R, Nakata B, Shigekawa M, Mizuno N, Sawaki A, Hirakawa K, Arakawa T, Yamao K. Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer. J Exp Clin Cancer Res 2009; 28: 83 [PMID: 19531250 DOI: 10.1186/1756-9966-28-83]